Corneal Keloid

Comprehensive Clinical Guide: Corneal Keloid

1. Introduction and Clinical Overview

A corneal keloid is a rare, benign, yet vision-threatening fibroproliferative lesion of the cornea. Unlike cutaneous keloids, which are characterized by the overgrowth of dense fibrous tissue following dermal injury, a corneal keloid represents an exuberant, disorganized stromal repair response. It typically manifests as an elevated, white, opaque, and firm mass that projects from the corneal surface.

While clinically rare, these lesions are significant due to their potential for rapid growth, severe astigmatic induction, and mechanical interference with eyelid function. They are fundamentally distinct from traditional corneal scars (leukomas) due to their progressive nature, proliferative histology, and tendency to recur even after surgical excision.

2. Etiology and Pathophysiology

The pathophysiology of corneal keloids is rooted in a dysregulated wound-healing response. Under normal conditions, corneal keratocytes transition into fibroblasts and myofibroblasts to repair structural defects. In the case of keloids, this process fails to terminate, leading to persistent myofibroblast activity and an excessive deposition of extracellular matrix (ECM).

Key Etiological Factors:

• Post-Traumatic/Surgical: The most common trigger. Previous penetrating keratoplasty (PKP), deep stromal lacerations, or severe chemical burns often serve as the inciting event.
• Chronic Inflammation: Long-standing ocular surface disease or chronic ulcerative keratitis can stimulate persistent keratocyte activation.
• Genetic Predisposition: While less documented than dermal keloids, some evidence suggests a familial or individual predisposition to abnormal wound healing.
• Immunological Factors: Aberrant TGF-beta (Transforming Growth Factor-beta) signaling is heavily implicated in the promotion of fibrosis and the inhibition of apoptosis in these cells.

Mechanism of Development

The lesion is characterized by:
1. Myofibroblast Transformation: High expression of alpha-smooth muscle actin ($\alpha$-SMA).
2. Collagen Disorganization: Deposition of disorganized, thick collagen bundles (predominantly Type I and Type III).
3. Vascularization: Often accompanied by superficial neovascularization, providing the metabolic demand for the growing mass.

3. Clinical Presentation and Staging

Patients typically present with a history of ocular trauma or surgery, followed by the gradual appearance of a white, raised corneal mass.

Standard Clinical Presentation:

• Visual Acuity: Significant reduction due to irregular astigmatism and central visual axis obstruction.
• Morphology: A dome-shaped, elevated, pearly-white mass.
• Associated Findings: Chronic conjunctival injection, symblepharon (in severe cases), and secondary glaucoma due to angle closure or chronic inflammation.

Proposed Staging System

4. Differential Diagnosis

Distinguishing a corneal keloid from other corneal opacities is critical for surgical planning.

• Corneal Dermoid: Usually congenital; contains hair follicles or sebaceous glands.
• Surgical/Traumatic Leukoma: A stable scar; lacks the proliferative, elevated morphology of a keloid.
• Corneal Intraepithelial Neoplasia (CIN): Often gelatinous or papilliform; lacks the dense, fibrous, "bulky" nature of a keloid.
• Squamous Cell Carcinoma (SCC): Often ulcerated or vascularized; requires biopsy to rule out malignancy.
• Pyogenic Granuloma: Highly vascular, friable, and red; distinct from the firm, white, fibrous keloid.

5. Diagnostic Workup

A definitive diagnosis is usually made via a combination of clinical assessment and histopathology.

1. Slit-Lamp Biomicroscopy: Essential for assessing the depth and vascularity of the lesion.
2. Anterior Segment OCT (AS-OCT): The gold standard for non-invasive imaging. It allows for the precise measurement of the lesion's depth within the corneal stroma and its relationship to the anterior chamber.
3. Ultrasound Biomicroscopy (UBM): Useful if the keloid is too dense to visualize the posterior structures or if glaucoma is suspected.
4. Histopathology (Post-Excision): Confirms the diagnosis by showing dense collagen bundles, spindle-shaped fibroblasts, and $\alpha$-SMA positivity on immunohistochemistry.

6. Management and Surgical Interventions

Management is predominantly surgical, yet the risk of recurrence is high, often necessitating adjuvant therapies.

Surgical Strategies:

• Lamellar Keratectomy: Removal of the keloid with preservation of healthy deep stroma.
• Penetrating Keratoplasty (PKP): Required if the lesion involves the full thickness of the cornea.
• Amniotic Membrane Transplantation (AMT): Used to promote healing and reduce inflammation post-excision.

Adjuvant Therapies to Prevent Recurrence:

• Mitomycin-C (MMC): Topical application (0.02%) during or after surgery to inhibit fibroblast proliferation.
• Subconjunctival/Intrastromal Corticosteroids: To suppress the inflammatory-fibrotic cascade.
• 5-Fluorouracil (5-FU): Occasionally used as an anti-metabolite to prevent recurrence.

7. Risks, Complications, and Prognosis

The long-term prognosis depends on the depth of the lesion and the success of preventing recurrence.

• Recurrence: The most significant risk. Keloids can regrow rapidly if the stimulus for myofibroblast activity is not fully mitigated.
• Glaucoma: Secondary to chronic inflammation or mechanical obstruction of the trabecular meshwork.
• Corneal Perforation: Rare, but possible during aggressive surgical excision of deep lesions.
• Graft Rejection: If PKP is performed, the patient remains at lifelong risk for immunological graft rejection.

8. Massive FAQ Section

1. Is a corneal keloid a type of cancer?
No. It is a benign, non-neoplastic, fibroproliferative disorder. It does not metastasize, but it is locally destructive.

2. Why does it recur after surgery?
The underlying trigger (trauma/inflammation) leaves a "memory" in the corneal stromal cells. Without adjuvant anti-metabolites like Mitomycin-C, the cells often revert to their proliferative state.

3. Can I wear contact lenses over a corneal keloid?
Generally, no. The irregular surface makes lens fitting impossible and increases the risk of infection and mechanical irritation.

4. What is the role of TGF-beta in this condition?
TGF-beta is a cytokine that promotes the transition of keratocytes into myofibroblasts. It is the primary biochemical driver of the keloid growth.

5. How is a corneal keloid different from a pterygium?
A pterygium is a fibrovascular growth originating from the conjunctiva onto the cornea. A corneal keloid originates from the corneal stroma itself.

6. Does the keloid hurt?
Most patients experience foreign body sensation, irritation, and redness. Severe pain may indicate secondary glaucoma or inflammation.

7. Is surgery always required?
For symptomatic or visually significant lesions, surgery is almost always required as they rarely stabilize or regress on their own.

8. What is the best imaging tool for diagnosis?
Anterior Segment OCT (AS-OCT) is the preferred tool for mapping the depth of the keloid before surgery.

9. Can Mitomycin-C cause side effects?
Yes. Excessive or improper use can lead to scleral thinning, corneal melting, or chronic epithelial defects. It must be used under strict clinical supervision.

10. What is the prognosis for vision?
Prognosis is guarded. While surgery can clear the visual axis, the induced astigmatism and potential for graft rejection mean that vision may require long-term correction (glasses or rigid gas permeable lenses).

9. Conclusion

The corneal keloid remains a diagnostic and therapeutic challenge in ophthalmology. Its management requires a sophisticated understanding of corneal wound healing and a multimodal approach involving meticulous surgical excision and aggressive anti-fibrotic prophylaxis. As research into myofibroblast inhibition continues to evolve, the prognosis for patients with this condition is gradually improving, moving from a cycle of chronic recurrence toward more stable, long-term ocular surface health.

Disclaimer: This guide is for educational purposes for medical professionals and does not constitute clinical advice. All clinical decisions regarding corneal keloid management must be tailored to the individual patient’s ocular history and systemic health status.